Search Results
238 items found for "Domain Therapeutics"
- Meet Peter McNamara, Ph.D., Tectonic’s SVP, Head of Research
We’re glad to have Peter's dedication, experience, and passion in building innovative therapeutics."
- Finding needles in haystacks: Omass unveils pipeline aimed at tough-to-drug targets
November 2021 "Nov. 15, 2021 LONDON – There’s not yet proof of the pudding, but Omass Therapeutics Ltd
- Accelerating GPCR Drug Discovery With Conformation-Stabilizing VHHs
June 2022 "G protein-coupled receptors (GPCRs) represent a major therapeutic target class as they play In 2019, 5 out of 20 first-in-class approved therapeutic agents targeted GPCRs.
- Addex Raises $10 Million In Equity Financing
December 2021 "Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq:
- Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with ...
Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with Tim Dyer Addex Therapeutics "Tim Dyer is the Co-Founder and CEO of Addex Therapeutics, which is focusing on the pharmacology known
- Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for...
Modulator Research Collaboration for Substance Use Disorders "Geneva, Switzerland, August 15, 2022 - Addex Therapeutics
- Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc. has...
Phase 1 studies in Japan with JNJ-40411813 (ADX71149) "Geneva, Switzerland, November 15, 2021 – Addex Therapeutics
- Developing the Cannabinoid Receptor 2 (CB2) pharmacopoeia: past, present, and future
Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with considerable, though as yet unrealised, therapeutic
- Developing the Cannabinoid Receptor 2 (CB2) pharmacopeia: past, present, and future
Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with considerable, though as yet unrealized, therapeutic
- Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment ...
Screening Platform Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 6, 2022 - Addex Therapeutics
- GPCRs Are Optimal Regulators of Complex Biological Systems and Orchestrate the Interface between ...
Orchestrate the Interface between Health and Disease GPCRs arguably represent the most effective current therapeutic Given the tremendous success of GPCRs as therapeutic targets, considerable focus has been placed on the ability of these therapeutics to modulate diseases by acting at cell surface receptors. GPCR superstructures, termed receptorsomes, both at the cell surface membrane and in the intracellular domain
- Nanobodies: New Dimensions in GPCR Signaling Research
Nanobodies (Nbs), known as variable antigen-binding (VHH) domain or single-domain antibodies, are small the development of more selective drugs capable of modulating specific signaling pathways, improving therapeutic This allows for tailoring the half-life of nanobodies to increase their therapeutic window depending its conformation, protects the Schiff base, and prevents protein degradation, potentially offering therapeutic Nanobodies: A Review of Generation, Diagnostics and Therapeutics.
- Nanobodies as Probes and Modulators of Cardiovascular G Protein-Coupled Receptors
In less than a decade, nanobodies, or recombinant single-domain antibody fragments from camelids, have nanobodies with tailored specificities may expand the impact of these tools for both basic science and therapeutic
- 📰 GPCR Weekly News, October 9 to 15, 2023
Adhesion GPCRs Piconewton Forces Mediate GAIN Domain Dissociation of the Latrophilin-3 Adhesion GPCR Unveiling Mechanical Activation: GAIN Domain Unfolding and Dissociation in Adhesion GPCRs GPCR Activation Tethered Ligands that Target the µ-Opioid Receptor Design and Synthesis of Novel GPR139 Agonists with Therapeutic
- Structural dynamics of Smoothened (SMO) in ciliary membrane and its interaction with membrane lipids
September 2022 "The Smoothened receptor (SMO, a 7 pass transmembrane domain, Class F GPCR family protein In the absence of HH signaling, SMO is inhibited by Patched 1 (PTC1; a 12 pass transmembrane domain protein We are able to identify the interaction of membrane cholesterols with definite sites and domains within domain (CRD) and the intracellular domain (ICD), are through residues belonging to known cholesterol-binding Structural analysis of SMO domains shows significant changes in the CRD and ICD, during the course of
- Structure of Mycobacterium tuberculosis Cya, an evolutionary ancestor of the mammalian membrane...
The TM helices 1–5 form a structurally conserved domain that facilitates the assembly of the helical and catalytic domains. Neutralization of the negatively charged extracellular pocket Ex1 destabilizes the cytosolic helical domain The TM domain acts as a functional component of Cya, guiding the assembly of the catalytic domain and
- 📰 GPCR Weekly News, April 17 to 23, 2023
GPCRs in Neuroscience G protein coupled receptors as targets for transformative neuropsychiatric therapeutics GPCRs in Oncology and Immunology CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment Methods & Updates in GPCR Research Solvent accessibility of a GPCR transmembrane domain probed by in-membrane Inversago Pharma will present at BBHIC 2023 Orion Biotechnology attended the Swiss Biotech Day Addex Therapeutics GPCR Events, Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics
- Precise druggability of the PTH type 1 receptor
molecules because their large orthosteric peptide-binding pocket embedded deep within the transmembrane domain PTHR signaling that could be extended to GPCRs to expedite discoveries of small molecules as novel therapeutic
- PH-Binding Motif in PAR4 Oncogene: From Molecular Mechanism to Drug Design
Point mutations are in the C-tail of PAR4 PH-binding domain; F347 L and D349A, but not E346A, abrogate Pc(4-4) may become a promising candidate for future therapeutic cancer treatment."
- 📰 GPCR Weekly News, August 14 to 20, 2023
Congrats to the GPCR Therapeutics team for their recent paper in the American College of Clinical Pharmacology GPCR Symposium on 'GPCRs as Therapeutic Modalities'. GPCR Activation and Signaling Single-molecule analysis reveals that a glucagon-bound extracellular domain and oligomerization Molecular Insights into GPCR Mechanisms for Drugs of Abuse Industry News 'GPCR Therapeutics Nordisk to Acquire Inversago Pharma GPCR Events, Meetings, and Webinars NEW Antiverse: Reimagining Therapeutic
- Regulators of G-protein signaling: essential players in GPCR signaling
are a family with around 20 members characterized by the presence of a conserved RGS-homology (RH) domain This domain contains the catalytic core that catalyzes the hydrolysis of guanosine triphosphate (GTP) In addition to the RGS domain, RGS proteins also contain a range of other structural motifs that are critical for their function, including the G protein-binding domain, the DEP (Dishevelled, Egl-10 and Pleckstrin domain) domain, and the GoLoco motif[2, 3].
- Cell Surface Calcium-Sensing Receptor Heterodimers: Mutant Gene Dosage Affects Ca 2+ Sensing but...
extracellular Venus flytrap (VFT) unit that activates G protein-dependent signaling via twin Cysteine-rich domains -293 cells were assessed for Ca2+o -stimulated Ca2+i mobilization using mutations in either the VFT domains When the same mutation was present in both VFT domains of receptor dimers, analogous to homozygous neonatal Mutant heterodimers containing one wild-type (WT) and one mutant VFT domain, however, corresponding to Thus two WT VFT domains were required for normal Ca2+o potency and there was a pronounced gene-dosage
- 📰 GPCR Weekly News, December 11 to 17, 2023
This week's highlights: Kudos to our partner, GPCR Therapeutics, for partnering with Bridge Biotherapeutics tANCHOR fast and cost-effective cell-based immunization approach with focus on the receptor-binding domain acids conjugation with [Cp*Rh(H2O)3]2+ by using the meta-dynamics/FMO3 approach Industry News GPCR Therapeutics - Providing the next generation of high-impact medicines Structure Therapeutics Provides Comprehensive Launches to Screen AI-Generated Virtual Libraries AbbVie to Acquire Cerevel Therapeutics in Transformative
- 📰 GPCR Weekly News, June 19 to 25, 2023
GPCR Partner, GPCR Therapeutics, for passing the Technology Evaluation process for listing on the KOSDAQ Reviews, GPCRs, and more 7TM domain structures of adhesion GPCRs: what's new and what's missing? GPCR Therapeutics passes the Technology Evaluation process for listing on KOSDAQ. function" (June 28 - 30, 2023) FREE Seminar Antibodies targeting Membrane Proteins - From Antigen to New Therapeutics
- TM5-TM6: structural switches that modulate the coupling of serotonin receptors to Gs or Gi
structures of four protein complexes integrated by a complete human serotonin receptor subtype and a dominant These differences are mainly attributed to the characteristic Ras domain distance between Gs and Gi. understanding how serotonin receptors, one of the largest subfamilies of class A GPCRs and potential therapeutic
- 📰 GPCR Weekly News, August 21 to 27, 2023
GPCR Symposium on 'GPCRs as Therapeutic Modalities'. neutrophil chemoattractant Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms and therapeutic Structural basis for the allosteric modulation of rhodopsin by nanobody binding to its extracellular domain Launches with $33 Million Seed Round to Fuel its Drug Discovery Engine and Pipeline of Small Molecule Therapeutics
- Integrative model of the FSH receptor reveals the structural role of the flexible hinge region
Structurally, the extensive extracellular domain, which contains the hormone-binding site and is linked to the transmembrane domain by the hinge region (HR), is characteristic for these receptors.
- Allosteric ligands control the activation of a class C GPCR heterodimer by acting at the transmembra
of action of positive allosteric modulators (PAMs) that bind at the interface of the transmembrane domains The data support the inference that they act at the active interface between both transmembrane domains agonist activity of these PAMs involves a key region in the central core of the GABAB2 transmembrane domain